Literature DB >> 14764528

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.

Jianmin Ding1, Hirokazu Komatsu, Atsushi Wakita, Miyuki Kato-Uranishi, Masato Ito, Atsushi Satoh, Kazuya Tsuboi, Masakazu Nitta, Hiroshi Miyazaki, Shinsuke Iida, Ryuzo Ueda.   

Abstract

One Japanese pedigree of familial essential thrombocythemia (FET) inherited in an autosomal-dominant manner is presented. A unique point mutation, serine 505 to asparagine 505 (Ser505Asn), was identified in the transmembrane domain of the c-MPL gene in all of the 8 members with thrombocythemia, but in none of the other 8 unaffected members in this FET family. The Ba/F3 cells expressing the mutant Asn505 acquired interleukin 3 (IL-3)-independent survival capacity, whereas those expressing wild-type Ser505 did not. The autonomous phosphorylation of Mek1/2 and Stat5b was observed in the mutant Ba/F3 cells in the absence of IL-3. The former was also found in platelets derived from the affected individual in the absence of thrombopoietin. These results show that the Asn505 is an activating mutation with respect to the intracellular signaling and survival of the cells. This is the first report of FET deriving from a dominant-positive activating mutation of the c-MPL gene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764528     DOI: 10.1182/blood-2003-10-3471

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  79 in total

1.  Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.

Authors:  Julia Asp; Björn Andréasson; Ulrika Hansson; Carina Wasslavik; Johanna Abelsson; Peter Johansson; Lars Palmqvist
Journal:  Haematologica       Date:  2016-01-14       Impact factor: 9.941

Review 2.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

3.  Synthetic Deletion of the Interleukin 23 Receptor (IL-23R) Stalk Region Led to Autonomous IL-23R Homodimerization and Activation.

Authors:  Thorben M Hummel; Theresa Ackfeld; Marco Schönberg; Gregor Ciupka; Falk Schulz; Anne Oberdoerster; Joachim Grötzinger; Jürgen Scheller; Doreen M Floss
Journal:  Mol Cell Biol       Date:  2017-08-11       Impact factor: 4.272

Review 4.  Megakaryocyte biology and related disorders.

Authors:  Liyan Pang; Mitchell J Weiss; Mortimer Poncz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

5.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 6.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

7.  Clinical utility gene card for: hereditary thrombocythemia.

Authors:  Kais Hussein; Melanie Percy; Mary Frances McMullin; Jiří Schwarz; Susanne Schnittger; Naomi Porret; Luz Maria Martinez-Aviles; Beatriz Bellosillo Paricio; Stéphane Giraudier; Radek Skoda; Eric Lippert; Sylvie Hermouet; Holger Cario
Journal:  Eur J Hum Genet       Date:  2013-06-05       Impact factor: 4.246

8.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

Review 9.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

10.  Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia.

Authors:  Kun Liu; Maurizio Martini; Bianca Rocca; Christopher I Amos; Luciana Teofili; Fiorina Giona; Jianmin Ding; Hirokazu Komatsu; Luigi M Larocca; Radek C Skoda
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.